#72 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
# Summary This article addresses the significant gap in coordinated surveillance systems for monitoring cannabis use and associated harms in youth populations, highlighting a critical challenge for understanding the true public health burden of adolescent cannabis exposure. The lack of standardized, integrated monitoring prevents clinicians and public health officials from accurately assessing prevalence trends, patterns of use, and developmental consequences across different regions and demographics. Current fragmented data collection efforts hamper the ability to identify emerging risks, such as the effects of high-potency products on adolescent brain development, and complicate efforts to establish evidence-based prevention and intervention strategies. For clinicians managing adolescent patients, this monitoring gap means reliance on incomplete information when counseling youth and families about cannabis risks during a critical neurodevelopmental period. The practical takeaway is that physicians should proactively screen all adolescent patients for cannabis use regardless of apparent risk factors, document their findings carefully, and advocate for improved surveillance infrastructure in their communities to better inform clinical decision-making and population-level prevention efforts.
“We still don’t have systematic surveillance tracking cannabis-related harm in adolescents the way we monitor other public health threats, which means we’re essentially flying blind on a generation of young users exposed to products that are exponentially more potent than what we studied even a decade ago.”
💭 As cannabis legalization expands across jurisdictions, clinicians should recognize that coordinated surveillance systems for youth cannabis use remain fragmented, making it challenging to track true prevalence, patterns of use, and emerging harms in real time. The absence of standardized, national monitoring creates a gap between clinical observations at the point of care and the epidemiologic picture needed to guide prevention and harm-reduction strategies. Key confounders complicate risk assessment, including variability in product potency and composition, differences in routes of administration, developmental timing of exposure, and the difficulty distinguishing correlation from causation in observational studies of adolescent outcomes. Despite these evidence gaps, clinicians encounter youth cannabis users regularly and should maintain awareness of documented concerns including impacts on neurodevelopment, motivation, academic performance, and mental health, while avoiding both alarmism and complacency. In practice, screening for cannabis use during adolescent visits and motivational conversations about timing and
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: